Elscint returns with biomedical investment fund:
This article was originally published in Clinica
Elscint, an Israeli company formerly known for its imaging businesses which it disposed of in 1998 for a total of $603 million, is moving back into early-stage biomedical investment. Elscint has set up Elscint BioMedical, a wholly owned subsidiary, funded with an initial $30 million to invest in early-stage companies in drug delivery, therapeutics and gene therapy. The company has already invested in Gamida Cell, another Israeli company, which is developing proprietary technology for multiplying embryonic stem cells.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.